Mailman School of Public Health, Columbia University, New York, New York2Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York.
Mailman School of Public Health, Columbia University, New York, New York2Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York3College of Physicians and Surgeons, Columbia University, New York, New York.
JAMA Oncol. 2016 Sep 1;2(9):1170-6. doi: 10.1001/jamaoncol.2016.0685.
Not all women initiate clinically indicated breast cancer adjuvant treatment. It is important for clinicians to identify women at risk for noninitiation.
To determine whether complementary and alternative medicine (CAM) use is associated with decreased breast cancer chemotherapy initiation.
DESIGN, SETTING, AND PARTICIPANTS: In this multisite prospective cohort study (the Breast Cancer Quality of Care [BQUAL] study) designed to examine predictors of breast cancer treatment initiation and adherence, 685 women younger than 70 years with nonmetastatic invasive breast cancer were recruited from Columbia University Medical Center, Kaiser Permanente Northern California, and Henry Ford Health System and enrolled between May 2006 and July 31, 2010. Overall, 306 patients (45%) were clinically indicated to receive chemotherapy per National Comprehensive Cancer Network guidelines. Participants were followed for up to 12 months.
Baseline interviews assessed current use of 5 CAM modalities (vitamins and/or minerals, herbs and/or botanicals, other natural products, mind-body self-practice, mind-body practitioner-based practice). CAM use definitions included any use, dietary supplement use, mind-body use, and a CAM index summing the 5 modalities.
Chemotherapy initiation was assessed via self-report up to 12 months after baseline. Multivariable logistic regression models examined a priori hypotheses testing whether CAM use was associated with chemotherapy initiation, adjusting for demographic and clinical covariates, and delineating groups by age and chemotherapy indication.
A cohort of 685 women younger than 70 years (mean age, 59 years; median age, 59 years) with nonmetastatic invasive breast cancer were recruited and followed for up to 12 months to examine predictors of breast cancer treatment initiation. Baseline CAM use was reported by 598 women (87%). Chemotherapy was initiated by 272 women (89%) for whom chemotherapy was indicated, compared with 135 women (36%) for whom chemotherapy was discretionary. Among women for whom chemotherapy was indicated, dietary supplement users and women with high CAM index scores were less likely than nonusers to initiate chemotherapy (odds ratio [OR], 0.16; 95% CI, 0.03-0.51; and OR per unit, 0.64; 95% CI, 0.46-0.87, respectively). Use of mind-body practices was not related to chemotherapy initiation (OR, 1.45; 95% CI, 0.57-3.59). There was no association between CAM use and chemotherapy initiation among women for whom chemotherapy was discretionary.
CAM use was high among patients with early-stage breast cancer enrolled in a multisite prospective cohort study. Current dietary supplement use and higher number of CAM modalities used but not mind-body practices were associated with decreased initiation of clinically indicated chemotherapy. Oncologists should consider discussing CAM with their patients during the chemotherapy decision-making process.
并非所有女性都会开始接受临床推荐的乳腺癌辅助治疗。临床医生识别出有不开始治疗风险的女性很重要。
确定补充和替代医学(CAM)的使用是否与降低乳腺癌化疗起始率有关。
设计、地点和参与者:本研究为多站点前瞻性队列研究(BQUAL 研究),旨在检查乳腺癌治疗开始和依从性的预测因素,纳入了 685 名年龄小于 70 岁的非转移性浸润性乳腺癌女性,她们来自哥伦比亚大学医学中心、凯撒永久医疗集团北加利福尼亚分校和亨利福特健康系统,并于 2006 年 5 月至 2010 年 7 月 31 日期间入组。总体而言,根据国家综合癌症网络指南,306 名患者(45%)有临床指征需要接受化疗。参与者的随访时间最长为 12 个月。
基线访谈评估了当前使用的 5 种 CAM 方式(维生素和/或矿物质、草药和/或植物药、其他天然产品、身心自我实践、身心从业者实践)。CAM 使用的定义包括任何使用、膳食补充剂使用、身心使用以及将 5 种方式相加的 CAM 指数。
通过自我报告在基线后最多 12 个月评估化疗起始情况。多变量逻辑回归模型根据年龄和化疗指征进行分层,以检验 CAM 使用与化疗起始相关的预先假设,同时调整人口统计学和临床协变量。
共招募了 685 名年龄小于 70 岁(平均年龄 59 岁;中位数年龄 59 岁)的非转移性浸润性乳腺癌女性,并随访了最多 12 个月,以检查乳腺癌治疗开始的预测因素。598 名女性(87%)报告了基线 CAM 使用情况。对于有化疗指征的女性,有 272 名(89%)开始接受化疗,而对于有化疗指征的女性,有 135 名(36%)开始接受化疗。在有化疗指征的女性中,与非使用者相比,膳食补充剂使用者和 CAM 指数得分较高的女性不太可能开始化疗(比值比[OR],0.16;95%置信区间[CI],0.03-0.51;每单位 OR,0.64;95%CI,0.46-0.87)。身心实践的使用与化疗起始无关(OR,1.45;95%CI,0.57-3.59)。在有化疗指征的女性中,CAM 使用与化疗起始之间没有关联。
在多站点前瞻性队列研究中,入组的早期乳腺癌患者中 CAM 使用情况较高。当前的膳食补充剂使用和更多的 CAM 方式使用,但不包括身心实践,与降低临床推荐的化疗起始率相关。肿瘤医生在化疗决策过程中应考虑与患者讨论 CAM。